<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39349594</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Deep learning for discriminating non-trivial conformational changes in molecular dynamics simulations of SARS-CoV-2 spike-ACE2.</ArticleTitle><Pagination><StartPage>22639</StartPage><MedlinePgn>22639</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">22639</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-72842-w</ELocationID><Abstract><AbstractText>Molecular dynamics (MD) simulations produce a substantial volume of high-dimensional data, and traditional methods for analyzing these data pose significant computational demands. Advances in MD simulation analysis combined with deep learning-based approaches have led to the understanding of specific structural changes observed in MD trajectories, including those induced by mutations. In this study, we model the trajectories resulting from MD simulations of the SARS-CoV-2 spike protein-ACE2, specifically the receptor-binding domain (RBD), as interresidue distance maps, and use deep convolutional neural networks to predict the functional impact of point mutations, related to the virus's infectivity and immunogenicity. Our model was successful in predicting mutant types that increase the affinity of the S protein for human receptors and reduce its immunogenicity, both based on MD trajectories (precision = 0.718; recall = 0.800; [Formula: see text] = 0.757; MCC = 0.488; AUC = 0.800) and their centroids. In an additional analysis, we also obtained a strong positive Pearson's correlation coefficient equal to 0.776, indicating a significant relationship between the average sigmoid probability for the MD trajectories and binding free energy (BFE) changes. Furthermore, we obtained a coefficient of determination of 0.602. Our 2D-RMSD analysis also corroborated predictions for more infectious and immune-evading mutants and revealed fluctuating regions within the receptor-binding motif (RBM), especially in the [Formula: see text] loop. This region presented a significant standard deviation for mutations that enable SARS-CoV-2 to evade the immune response, with RMSD values of 5Å in the simulation. This methodology offers an efficient alternative to identify potential strains of SARS-CoV-2, which may be potentially linked to more infectious and immune-evading mutations. Using clustering and deep learning techniques, our approach leverages information from the ensemble of MD trajectories to recognize a broad spectrum of multiple conformational patterns characteristic of mutant types. This represents a strategic advantage in identifying emerging variants, bypassing the need for long MD simulations. Furthermore, the present work tends to contribute substantially to the field of computational biology and virology, particularly to accelerate the design and optimization of new therapeutic agents and vaccines, offering a proactive stance against the constantly evolving threat of COVID-19 and potential future pandemics.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moraes Dos Santos</LastName><ForeName>Lucas</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Computer Science, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. lucas.santos@dcc.ufmg.br.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gutembergue de Mendonça</LastName><ForeName>José</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Federal University of Paraíba, João Pessoa, Paraíba, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jerônimo Gomes Lobo</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Exact and Biological Sciences, Federal University of São João Del Rei, São João del Rei, Minas Gerais, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henrique Franca de Lima</LastName><ForeName>Leonardo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Exact and Biological Sciences, Federal University of São João Del Rei, São João del Rei, Minas Gerais, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruno Rocha</LastName><ForeName>Gerd</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Federal University of Paraíba, João Pessoa, Paraíba, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>C de Melo-Minardi</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Computer Science, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. raquelcm@dcc.ufmg.br.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077321" MajorTopicYN="Y">Deep Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056004" MajorTopicYN="Y">Molecular Dynamics Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="Y">Angiotensin-Converting Enzyme 2</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072417" MajorTopicYN="N">Protein Domains</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CNNs</Keyword><Keyword MajorTopicYN="N">Deep learning</Keyword><Keyword MajorTopicYN="N">Distance maps</Keyword><Keyword MajorTopicYN="N">Molecular dynamics</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>23</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39349594</ArticleId><ArticleId IdType="pmc">PMC11443059</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-72842-w</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-72842-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Min, S., Lee, B. &amp; Yoon, S. Deep learning in bioinformatics. Brief. Bioinform.18, 851–869. 10.1093/bib/bbw068 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27473064</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodfellow, I. J., Bengio, Y. &amp; Courville, A. Deep Learning (MIT Press, 2016).</Citation></Reference><Reference><Citation>Zhang, A., Lipton, Z. C., Li, M. &amp; Smola, A. J. Dive into Deep Learning (Cambridge University Press, 2023).</Citation></Reference><Reference><Citation>Gao, W. et al. Deep learning in protein structural modeling and design. Patterns1, 100142. 10.1016/j.patter.2020.100142 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7733882</ArticleId><ArticleId IdType="pubmed">33336200</ArticleId></ArticleIdList></Reference><Reference><Citation>Defresne, M., Barbe, S. &amp; Schiex, T. Protein design with deep learning. Int. J. Mol. Sci.22, 11741. 10.3390/ijms222111741 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8584038</ArticleId><ArticleId IdType="pubmed">34769173</ArticleId></ArticleIdList></Reference><Reference><Citation>Senior, A. W. et al. Improved protein structure prediction using potentials from deep learning. Nature577, 706–710. 10.1038/s41586-019-1923-7 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31942072</ArticleId></ArticleIdList></Reference><Reference><Citation>Plante, A. et al. A machine learning approach for the discovery of ligand-specific functional mechanisms of GPCRs. Molecules24, 2097. 10.3390/molecules24112097 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6600179</ArticleId><ArticleId IdType="pubmed">31159491</ArticleId></ArticleIdList></Reference><Reference><Citation>Han, M. et al. Recognition of the ligand-induced spatiotemporal residue pair pattern of [Image: see text] 2-adrenergic receptors using 3-D residual networks trained by the time series of protein distance maps. Comput. Struct. Biotechnol. J.20, 6360–6374. 10.1016/j.csbj.2022.10.036 (2022).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9677134</ArticleId><ArticleId IdType="pubmed">36420156</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, C. et al. An interpretable convolutional neural network framework for analyzing molecular dynamics trajectories: A case study on functional states for G-protein-coupled receptors. J. Chem. Inf. Model.62, 1399–1410. 10.1021/acs.jcim.2c00085 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35257580</ArticleId></ArticleIdList></Reference><Reference><Citation>Karplus, M. &amp; McCammon, J. A. Molecular dynamics simulations of biomolecules. Nat. Struct. Biol.9, 646–652. 10.1038/nsb0902-646 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12198485</ArticleId></ArticleIdList></Reference><Reference><Citation>Filipe, H. A. L. &amp; Loura, L. M. S. Molecular dynamics simulations: Advances and applications. Molecules27, 2105. 10.3390/molecules27072105 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9000824</ArticleId><ArticleId IdType="pubmed">35408504</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingsworth, S. A. &amp; Dror, R. O. Molecular dynamics simulation for all. Neuron99, 1129–1143. 10.1016/j.neuron.2018.08.011 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6209097</ArticleId><ArticleId IdType="pubmed">30236283</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, X. et al. Deep geometric representations for modeling effects of mutations on protein–protein binding affinity. PLoS Comput. Biol.17, e1009284. 10.1371/journal.pcbi.1009284 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8366979</ArticleId><ArticleId IdType="pubmed">34347784</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannar, D. et al. Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding. Cell Rep.37, 110156. 10.1016/j.celrep.2021.110156 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8642162</ArticleId><ArticleId IdType="pubmed">34914928</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, J. et al. Mutations strengthened SARS-CoV-2 infectivity. J. Mol. Biol.432, 5212–5226. 10.1016/j.jmb.2020.07.009 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7375973</ArticleId><ArticleId IdType="pubmed">32710986</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, W.-T. et al. SARS-CoV-2 e484k mutation narrative review: Epidemiology, immune escape, clinical implications, and future considerations. Infecti. Drug Resist.15, 373–385. 10.2147/idr.s344099 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8820839</ArticleId><ArticleId IdType="pubmed">35140483</ArticleId></ArticleIdList></Reference><Reference><Citation>Sergeeva, A. P. et al. Free energy perturbation calculations of mutation effects on SARS-CoV-2 RBD:ACE2 binding affinity. J. Mol. Biol.435, 168187. 10.1016/j.jmb.2023.168187 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10286572</ArticleId><ArticleId IdType="pubmed">37355034</ArticleId></ArticleIdList></Reference><Reference><Citation>Baum, A. et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science369, 1014–1018. 10.1126/science.abd0831 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299283</ArticleId><ArticleId IdType="pubmed">32540904</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockx, B. et al. Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus. J. Infect. Dis.201, 946–955. 10.1086/651022 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2826557</ArticleId><ArticleId IdType="pubmed">20144042</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, G. et al. Deep-learning-enabled protein–protein interaction analysis for prediction of SARS-CoV-2 infectivity and variant evolution. Nat. Med.29, 2007–2018. 10.1038/s41591-023-02483-5 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37524952</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou, J. et al. V367f mutation in SARS-CoV-2 spike RBD emerging during the early transmission phase enhances viral infectivity through increased human ACE2 receptor binding affinity. J. Virol.[SPACE]10.1128/jvi.00617-21 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8373230</ArticleId><ArticleId IdType="pubmed">34105996</ArticleId></ArticleIdList></Reference><Reference><Citation>Pipitò, L., Rujan, R., Reynolds, A. C. &amp; Deganutti, G. Molecular dynamics studies reveal structural and functional features of the SARS-CoV-2 spike protein. BioEssays[SPACE]10.1002/bies.202200060 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9350306</ArticleId><ArticleId IdType="pubmed">35843871</ArticleId></ArticleIdList></Reference><Reference><Citation>Rath, S., Padhi, K. &amp; Mandal, N. Scanning the RBD-ACE2 molecular interactions in omicron variant. Biochem. Biophys. Res. Commun.592, 18–23. 10.1016/j.bbrc.2022.01.006 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8732900</ArticleId><ArticleId IdType="pubmed">35007846</ArticleId></ArticleIdList></Reference><Reference><Citation>Abduljalil, J. et al. How helpful were molecular dynamics simulations in shaping our understanding of SARS-CoV-2 spike protein dynamics?. Int. J. Biol. Macromol.242, 125153. 10.1016/j.ijbiomac.2023.125153 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10232722</ArticleId><ArticleId IdType="pubmed">37268078</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahamad, S., Hema, K. &amp; Gupta, D. Structural stability predictions and molecular dynamics simulations of RBD and HR1 mutations associated with SARS-CoV-2 spike glycoprotein. J. Biomol. Struct. Dyn.40, 6697–6709. 10.1080/07391102.2021.1889671 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33618621</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavlova, A. et al. Machine learning reveals the critical interactions for SARS-CoV-2 spike protein binding to ace2. J. Phys. Chem. Lett.12, 5494–5502. 10.1021/acs.jpclett.1c01494 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34086459</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, J. et al. Characterization of SARS-CoV-2 worldwide transmission based on evolutionary dynamics and specific viral mutations in the spike protein. Infect. Dis. Poverty.[SPACE]10.1186/s40249-021-00895-4 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8379592</ArticleId><ArticleId IdType="pubmed">34419160</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams, J. et al. Molecular dynamics analysis of a flexible loop at the binding interface of the SARS-CoV-2 spike protein receptor-binding domain. Proteins: Struct. Funct. Bioinform.90, 1044–1053. 10.1002/prot.26208 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8441656</ArticleId><ArticleId IdType="pubmed">34375467</ArticleId></ArticleIdList></Reference><Reference><Citation>Antony, P. &amp; Vijayan, R. Molecular dynamics simulation study of the interaction between human angiotensin converting enzyme 2 and spike protein receptor binding domain of the SARS-CoV-2 b.1.617 variant. Biomolecules11, 1244. 10.3390/biom11081244 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8391770</ArticleId><ArticleId IdType="pubmed">34439910</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol.19, 409–424. 10.1038/s41579-021-00573-0 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8167834</ArticleId><ArticleId IdType="pubmed">34075212</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrödinger, LLC. The PyMOL molecular graphics system (2020).</Citation></Reference><Reference><Citation>Waterhouse, A. et al. SWISS-MODEL: Homology modelling of protein structures and complexes. Nucleic Acids Res.46, W296–W303. 10.1093/nar/gky427 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6030848</ArticleId><ArticleId IdType="pubmed">29788355</ArticleId></ArticleIdList></Reference><Reference><Citation>Anandakrishnan, R., Aguilar, B. &amp; Onufriev, A. V. H [Image: see text] 3.0: Automating pK prediction and the preparation of biomolecular structures for atomistic molecular modeling and simulations. Nucleic Acids Res.40, W537–W541. 10.1093/nar/gks375 (2012).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3394296</ArticleId><ArticleId IdType="pubmed">22570416</ArticleId></ArticleIdList></Reference><Reference><Citation>Case, D. A. et al. The Amber biomolecular simulation programs. J. Comput. Chem.26, 1668–1688. 10.1002/jcc.20290 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1989667</ArticleId><ArticleId IdType="pubmed">16200636</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips, J. C. et al. Scalable molecular dynamics with NAMD. J. Comput. Chem.26, 1781–1802. 10.1002/jcc.20289 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2486339</ArticleId><ArticleId IdType="pubmed">16222654</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe, D. R. &amp; Cheatham, T. E. PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data. J. Chem. Theory Comput.9, 3084–3095. 10.1021/ct400341p (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">26583988</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature579, 265–269. 10.1038/s41586-020-2008-3 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094943</ArticleId><ArticleId IdType="pubmed">32015508</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. SARS-CoV-2 Variant Classifications and Definitions. https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html (2023).</Citation></Reference><Reference><Citation>Radvak, P. et al. SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains. Nat. Commun.12, 6559. 10.1038/s41467-021-26803-w (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8589842</ArticleId><ArticleId IdType="pubmed">34772941</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature593, 130–135. 10.1038/s41586-021-03398-2 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33684923</ArticleId></ArticleIdList></Reference><Reference><Citation>Faria, N. R. et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science372, 815–821. 10.1126/science.abh264 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8139423</ArticleId><ArticleId IdType="pubmed">33853970</ArticleId></ArticleIdList></Reference><Reference><Citation>Naveca, F. G. et al. COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence. Nat. Med.27, 1230–1238. 10.1038/s41591-021-01378-7 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34035535</ArticleId></ArticleIdList></Reference><Reference><Citation>Mlcochova, P. et al. SARS-CoV-2 B.1.617.2 delta variant replication and immune evasion. Nature599, 114–119. 10.1038/s41586-021-03944-y (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8566220</ArticleId><ArticleId IdType="pubmed">34488225</ArticleId></ArticleIdList></Reference><Reference><Citation>Pouwels, K. B. et al. Effect of delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat. Med.27, 2127–2135. 10.1038/s41591-021-01548-7 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8674129</ArticleId><ArticleId IdType="pubmed">34650248</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, W. et al. Emergence of a novel SARS-CoV-2 variant in southern California. JAMA325, 1324. 10.1001/jama.2021.1612 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7879386</ArticleId><ArticleId IdType="pubmed">33571356</ArticleId></ArticleIdList></Reference><Reference><Citation>Annavajhala, M. K. et al. Emergence and expansion of SARS-CoV-2 b.1.526 after identification in New York. Nature597, 703–708. 10.1038/s41586-021-03908-2 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8481122</ArticleId><ArticleId IdType="pubmed">34428777</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, H. et al. B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies. mBio12, e0138621. 10.1128/mbio.01386-21 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8406170</ArticleId><ArticleId IdType="pubmed">34311587</ArticleId></ArticleIdList></Reference><Reference><Citation>McCallum, M. et al. Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variants. Science374, 1621–1626. 10.1126/science.abl8506 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34751595</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilhelm, A. et al. Antibody-mediated neutralization of authentic SARS-CoV-2 b.1.617 variants harboring l452r and t478k/e484q. Viruses13, 1693. 10.3390/v13091693 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8473269</ArticleId><ArticleId IdType="pubmed">34578275</ArticleId></ArticleIdList></Reference><Reference><Citation>Halfmann, P. J. et al. Characterization of the SARS-CoV-2 b.1.621 (mu) variant. Sci. Transl. Med.14, eabm4908. 10.1126/scitranslmed.abm4908 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9392899</ArticleId><ArticleId IdType="pubmed">35579540</ArticleId></ArticleIdList></Reference><Reference><Citation>Laiton-Donato, K. et al. Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2. Infect. Genet. Evolut.95, 105038. 10.1016/j.meegid.2021.105038 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8364171</ArticleId><ArticleId IdType="pubmed">34403832</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, J. et al. Omicron variant (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance. J. Chem. Inf. Model.62, 412–422. 10.1021/acs.jcim.1c01451 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8751645</ArticleId><ArticleId IdType="pubmed">34989238</ArticleId></ArticleIdList></Reference><Reference><Citation>Haw, N. J. et al. Epidemiological characteristics of the SARS-CoV-2 Theta variant (P.3) in the Central Visayas region, Philippines, 30 October 2020–16 February 2021. West. Pac. Surveill. Resp. J.13, 60–62. 10.5365/wpsar.2022.13.1.883 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8935296</ArticleId><ArticleId IdType="pubmed">35355903</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Tracking SARS-CoV-2 variants. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ (2020).</Citation></Reference><Reference><Citation>Aksamentov, I. et al. Nextclade: Clade assignment, mutation calling and quality control for viral genomes. J. Open Source Soft.6, 3773. 10.21105/joss.03773 (2021).</Citation></Reference><Reference><Citation>Hodcroft, E. B. Covariants: SARS-CoV-2 Mutations and Variants of Interest[SPACE]https://covariants.org/ (2021).</Citation></Reference><Reference><Citation>Teng, S. et al. Systemic effects of missense mutations on SARS-CoV-2 spike glycoprotein stability and receptor-binding affinity. Brief. Bioinform.22, 1239–1253. 10.1093/bib/bbaa233 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665319</ArticleId><ArticleId IdType="pubmed">33006605</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurini, E. et al. Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies. Sci. Rep.11, 20274. 10.1038/s41598-021-99827-3 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8511038</ArticleId><ArticleId IdType="pubmed">34642465</ArticleId></ArticleIdList></Reference><Reference><Citation>Murtagh, F. A survey of recent advances in hierarchical clustering algorithms. Comput. J.26, 354–359. 10.1093/comjnl/26.4.354 (1983).</Citation></Reference><Reference><Citation>Kloczkowski, A. et al. Distance matrix-based approach to protein structure prediction. J. Struct. Funct. Genomics10, 67–81. 10.1007/s10969-009-9062-2 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3018873</ArticleId><ArticleId IdType="pubmed">19224393</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding, W. &amp; Gong, H. Predicting the real-valued inter-residue distances for proteins. Adv. Sci.[SPACE]10.1002/advs.202001314 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7539185</ArticleId><ArticleId IdType="pubmed">33042750</ArticleId></ArticleIdList></Reference><Reference><Citation>Du, Y., Kabir, A., Zhao, L. &amp; Shehu, A. From interatomic distances to protein tertiary structures with a deep convolutional neural network. in Proceedings of the 11th ACM International Conference on Bioinformatics, Computational Biology and Health Informatics 1–8 (2020). 10.1145/3388440.3414699.</Citation></Reference><Reference><Citation>Leach, A. Molecular Modeling: Principles and Applications 2nd edn. (Prentice Hall, 2001).</Citation></Reference><Reference><Citation>Simonyan, K. &amp; Zisserman, A. Very deep convolutional networks for large-scale image recognition. in 3rd International Conference on Learning Representations (ICLR 2015) 1–14 (2015). ArXiv:1409.1556v6.</Citation></Reference><Reference><Citation>LeCun, Y. Backpropagation applied to handwritten zip code recognition. Neural Comput.1, 541–551. 10.1162/neco.1989.1.4.541 (1989).</Citation></Reference><Reference><Citation>Chollet, F. Deep Learning with Python 4th edn. (Manning, 2017).</Citation></Reference><Reference><Citation>Mishkin, D., Sergievskiy, N. &amp; Matas, J. Systematic evaluation of convolution neural network advances on the Imagenet. Comput. Vis. Image Understand.[SPACE]10.1016/j.cviu.2017.05.007 (2017).</Citation></Reference><Reference><Citation>Ioffe, S. &amp; Szegedy, C. Batch normalization: Accelerating deep network training by reducing internal covariate shift. in Proceedings of the 32nd International Conference on International Conference on Machine Learning, vol. 37, 448—456 (2015).</Citation></Reference><Reference><Citation>Srivastava, N. et al. Dropout: A simple way to prevent neural networks from overfitting. J. Mach. Learn. Res.15, 1929–1958 (2014).</Citation></Reference><Reference><Citation>Abadi, M. et al.TensorFlow: Large-Scale Machine Learning on Heterogeneous Distributed Systems[SPACE]arXiv:1603.04467 (2016)</Citation></Reference><Reference><Citation>Sanches, P. R. S. et al. Recent advances in SARS-CoV-2 Spike protein and RBD mutations comparison between new variants Alpha (B.1.1.7, United Kingdom), Beta (B.1.351, South Africa), Gamma (P.1, Brazil) and Delta (B.1.617.2, India). J. Virus Erad.7, 100054. 10.1016/j.jve.2021.100054 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8443533</ArticleId><ArticleId IdType="pubmed">34548928</ArticleId></ArticleIdList></Reference><Reference><Citation>Duda, R. O., Hart, P. E. &amp; Stork, D. G. Pattern Classification (Wiley, 2001).</Citation></Reference><Reference><Citation>Haykin, S. Neural Networks (Prentice Hall, 1999).</Citation></Reference><Reference><Citation>Cherian, S. et al. SARS-CoV-2 spike mutations, L452R, T478K, E484Q and P681R, in the second Wave of COVID-19 in Maharashtra. India. Microorgan.9, 1542–1553. 10.3390/microorganisms9071542 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8307577</ArticleId><ArticleId IdType="pubmed">34361977</ArticleId></ArticleIdList></Reference><Reference><Citation>Webb, A. R. &amp; Copsey, K. D. Statistical Pattern Recognition (Wiley, 2011).</Citation></Reference><Reference><Citation>Dai, L. &amp; Gao, G. F. Viral targets for vaccines against COVID-19. Nat. Rev. Immunol.21, 73–82. 10.1038/s41577-020-00480-0 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7747004</ArticleId><ArticleId IdType="pubmed">33340022</ArticleId></ArticleIdList></Reference><Reference><Citation>Tada, T. et al. SARS-CoV-2 lambda variant remains susceptible to neutralization by mRNA vaccine-elicited antibodies and convalescent serum (2021). 10.1101/2021.07.02.450959.</Citation></Reference><Reference><Citation>Wang, M. et al. Reduced sensitivity of the SARS-CoV-2 lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination. Emerg. Microb. Infect.11, 18–29. 10.1080/22221751.2021.2008775 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8725979</ArticleId><ArticleId IdType="pubmed">34818119</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai, W. et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: Implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell. Mol. Immunol.17, 613–620. 10.1038/s41423-020-0400-4 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7091888</ArticleId><ArticleId IdType="pubmed">32203189</ArticleId></ArticleIdList></Reference><Reference><Citation>Alaofi, A. L. &amp; Shahid, M. Mutations of SARS-CoV-2 RBD may alter its molecular structure to improve its infection efficiency. Biomolecules11, 1273. 10.3390/biom11091273 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8466379</ArticleId><ArticleId IdType="pubmed">34572486</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul, D., Pyne, N. &amp; Paul, S. Mutation profile of SARS-CoV-2 spike protein and identification of potential multiple epitopes within spike protein for vaccine development against SARS-CoV-2. VirusDisease32, 703–726. 10.1007/s13337-021-00747-7 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8569294</ArticleId><ArticleId IdType="pubmed">34754886</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao, K. et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat. Rev. Genet.22, 757–773. 10.1038/s41576-021-00408-x (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8447121</ArticleId><ArticleId IdType="pubmed">34535792</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, J., Gao, K., Wang, R. &amp; Wei, G.-W. Prediction and mitigation of mutation threats to COVID-19 vaccines and antibody therapies. Chem. Sci.12, 6929–6948. 10.1039/d1sc01203g (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8153213</ArticleId><ArticleId IdType="pubmed">34123321</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, M., Cang, Z. &amp; Wei, G.-W. A topology-based network tree for the prediction of protein–protein binding affinity changes following mutation. Nat. Mach. Intell.2, 116–123. 10.1038/s42256-020-0149-6 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7223817</ArticleId><ArticleId IdType="pubmed">34170981</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, R. et al. Emerging vaccine-breakthrough SARS-CoV-2 variants. ACS Infect. Dis.8, 546–556. 10.1021/acsinfecdis.1c00557 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8848511</ArticleId><ArticleId IdType="pubmed">35133792</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, J. et al. Revealing the threat of emerging SARS-CoV-2 mutations to antibody therapies. J. Mol. Biol.433, 167155. 10.1016/j.jmb.2021.167155 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8277955</ArticleId><ArticleId IdType="pubmed">34273397</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, J., Gao, K., Wang, R. &amp; Wei, G. Revealing the threat of emerging SARS-CoV-2 mutations to antibody therapies. J. Mol. Biol.433, 167155. 10.1016/j.jmb.2021.167155 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8277955</ArticleId><ArticleId IdType="pubmed">34273397</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra, P. M., Anjum, F., Uversky, V. N. &amp; Nandi, C. K. SARS-CoV-2 spike mutations modify the interaction between virus spike and human ACE2 receptors. Biochem. Biophys. Res. Commun.620, 8–14. 10.1016/j.bbrc.2022.06.064 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9221686</ArticleId><ArticleId IdType="pubmed">35772213</ArticleId></ArticleIdList></Reference><Reference><Citation>Molnar, C. Interpretable Machine Learning: A Guide for Making Black Box Models Explainable (2022).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>